Andrea Janíková - Concepedia

Author

Andrea Janíková

Also Known As

A Janikova, A Janíková, A. JANIKOVA, A. Janikova, A. Janíková, Andrea JANÍKOVÁ, Andrea Janikova, Andrea Janiková, Andrea Janíková, Andrea Janíková (603930)

273

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University Hospital Brno Masaryk University Charles University Central European Institute of Technology – Masaryk University Central European Institute of Technology

About

Andrea Janíková is an author at University Hospital Brno specializing in pathology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	419
2	Health Sciences	4	4	212
3	Blood Transplantation	1	1	41
4	Cell Biology	1	1	56
5	Cellular Therapies	1	1	33

Andrea Janíková

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Positron Emission Tomography–Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants Judith Trotman, Marion Fournier, T. Lamy, Journal of Clinical Oncology	2011	216
Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study Antonio Salar, Irit Avivi, Beate Bittner, Journal of Clinical Oncology Phase Ib StudyIv RituximabLymphoid NeoplasiaRituximab SerumMedicine	2014	92
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels Kateřina Musilová, Ján Deván, Kateřina Amruz Černá, Blood	2018	72
Value of [18F]Fluorodeoxyglucose Positron Emission Tomography in the Management of Follicular Lymphoma: The End of a Dilemma? Andrea Janíková, Karol Bolčák, Tomáš Pavlík, Clinical Lymphoma & Myeloma Positron Emission TomographyLymphoid NeoplasiaMedical ImagingFollicular LymphomaPathology	2008	66
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy Marek Trněný, Gregor Verhoef, Martin J.S. Dyer, Haematologica	2018	60
Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target Hugo Larose, Nina Prokoph, Jamie D. Matthews, Haematologica ImmunologyToxic Multi-agent ChemotherapyPathologyCancer BiologyTumor Biology	2020	56
<i>miR-29</i> modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors Sonali Sharma, Gabriela Mladonická Pavlasová, Václav Šeda, Blood	2021	56
Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study Chan Y. Cheah, David Belada, Michelle A. Fanale, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaOpen-label Phase 1B/2MedicineImmunology	2015	45
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia Barbara Maurer, Harini Nivarthi, Bettina Wingelhofer, Haematologica	2019	43
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) Eva González‐Barca, Ariane Boumendil, Didier Blaise, Bone Marrow Transplantation Hematological MalignancyLymphoid NeoplasiaLymphoma Working PartyTransplantationMarrow Transplantation	2019	41

Page 1